News
![Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis (NASDAQ: EXEL) was one of the top biotech stocks of 2016. It's also one of the best biotech stocks so far this year. However, Exelixis shares have pulled back in recent days, primarily....
![2 Dividend Stocks You Can Buy and Hold Forever](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
2 Dividend Stocks You Can Buy and Hold Forever
If you'd like to park your money in stocks and monitor them as little as possible, you need to choose them extra carefully. There's no guarantee that even today's most successful companies won't....
![Does Teva's Terrible Tumble Make Its Stock a Buy?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Does Teva's Terrible Tumble Make Its Stock a Buy?
Disappointing financial results, a dividend cut, and reduced guidance have caused Teva Pharmaceutical Industries (NYSE: TEVA) shares to lose half their value in the past month. Can a restructuring....
![CAR-T Mania: Could Juno Therapeutics Get Acquired Next?](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
CAR-T Mania: Could Juno Therapeutics Get Acquired Next?
Gilead Sciences (NASDAQ: GILD) recently acquired Kite Pharma (NASDAQ: KITE), but that doesn't mean an acquisition of Juno Therapeutics (NASDAQ: JUNO) is off the table. Juno Therapeutics'....
![3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
Every biotech company goes into a clinical study with great hopes -- and often great fears, as well. There's no guarantee that all will go well. All the time and money poured into an experimental....
![ALPHA MOS : MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES A L'ASSEMBLEE GENERALE MIXTE DU 29 SEPTEMBRE 2017](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
ALPHA MOS : MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES A L'ASSEMBLEE GENERALE MIXTE DU 29 SEPTEMBRE 2017
Les actionnaires de la société Alpha MOS sont invités à participer à une assemblée générale mixte qui se tiendra le 29 septembre 2017 à 10 heures.
Au siège social de la société :
Immeuble Le....
![Here's Why United Therapeutics Sank as Much as 10.8% Today](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Here's Why United Therapeutics Sank as Much as 10.8% Today
Shares of rare-disease specialist United Therapeutics (NASDAQ: UTHR) dropped nearly 11% today after the company announced that a phase 3 trial evaluating Orenitram in patients with pulmonary....
![Why NewLink Genetics Is Soaring 37.5% Higher Today](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Why NewLink Genetics Is Soaring 37.5% Higher Today
After NewLink Genetics Corporation (NASDAQ: NLNK) updated data from its ongoing phase 2 trial of IDO inhibitor indoximod in advanced melanoma, shares in the immuno-oncology specialist shot higher....
![2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Shares of Exelixis (NASDAQ: EXEL), a biotech company primarily focused on developing drugs to treat cancer, rallied more than $2 per share during the month of August, according to data from....
![This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August
Shares of Valeant Pharmaceuticals (NYSE: VRX), a drugmaker that has predominantly grown via acquisitions over the years, plunged by 18% during August, according to data from S&P Global Market....
![A Perfect Storm Cut Teva Pharmaceutical Industries's Stock in Half in August](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
A Perfect Storm Cut Teva Pharmaceutical Industries's Stock in Half in August
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), an Israeli-based developer of branded and generic drugs, imploded in August and lost 51% of its market cap, according to data from S&P....
![The 5 Worst Reasons to Buy Marijuana Stocks](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
The 5 Worst Reasons to Buy Marijuana Stocks
Chances are you'd struggle to find an industry that's been stronger over the trailing one-year period than legal marijuana. Cannabis research firm ArcView pegged North American legal weed growth....
![Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products. All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved....
![Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
![Why Intra-Cellular Therapies Is Surging Today](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Why Intra-Cellular Therapies Is Surging Today
Shares of Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage pharma company focused on diseases of the central nervous system, jumped more than 17% as of 3:15 p.m. EDT on Thursday. The....
![Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August
Editas Medicine (NASDAQ: EDIT) is researching the use of gene editing to treat disease. After the company updated investors on its progress on Aug. 9, shares soared 18.8% last month, according to....
![AbbVie Scores 2 Wins: 1 Threatens Regeneron](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
![Are These Healthcare Stocks Top Takeover Targets?](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Are These Healthcare Stocks Top Takeover Targets?
Following Gilead Sciences' (NASDAQ: GILD) decision to buy Kite Pharma (NASDAQ: KITE) for $11.9 billion in cash, we couldn't help but wonder what other healthcare stocks could be takeover targets,....
![Why Clovis Oncology Fell 7.1% in August](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed....
![Are You Buying Gilead Sciences, Inc. for the Wrong Reason?](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Are You Buying Gilead Sciences, Inc. for the Wrong Reason?
Gilead Sciences (NASDAQ: GILD) is up about 12% over the last week or so since Novartis (NYSE: NVS) got its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah approved by the FDA.That's just....
![QUANTUM GENOMICS : Présentation de Quantum Genomics à la conférence Rodman et Renshaw 2017](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QUANTUM GENOMICS : Présentation de Quantum Genomics à la conférence Rodman et Renshaw 2017
Paris, le 7 septembre 2017
Quantum Genomics (Euronext Growth − FR0011648971 − ALQGC), société biopharmaceutique spécialisée dans le développement de nouvelles thérapies pour des besoins....
![Quantum Genomics to Present at Rodman and Renshaw 19th Annual Global Investment Conference](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quantum Genomics to Present at Rodman and Renshaw 19th Annual Global Investment Conference
Paris & New York, September 7, 2017
Quantum Genomics (Euronext Growth − FR001164897 − ALQGC; OTCQX: QNNTF), a biopharmaceutical company with the mission of developing new therapies for....
![BOIRON : 2017 half-year results](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
BOIRON : 2017 half-year results
(Data have been the subject to a limited review by the statutory auditors)
The Board of Directors of BOIRON, at its meeting of September 7, 2017, made up the half-year statutory and....
![BOIRON : Résultats semestriels 2017](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
BOIRON : Résultats semestriels 2017
(Données ayant fait l'objet d'une revue limitée par les commissaires aux comptes)
Le Conseil d'Administration de BOIRON, réuni le 7 septembre 2017, a établi les comptes sociaux et les comptes....
![Here's Why Shire PLC Stock Fell 10% in August](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Here's Why Shire PLC Stock Fell 10% in August
Shares of Shire PLC (NASDAQ: SHPG), a biopharmaceutical company that focuses on treatments for rare diseases, fell 9.94% in August, according to data from S&P Global Market Intelligence.....